CDH5 and neoplasm: Another FDA-approved mAb, anti-VE-cadherin antibody (E4G10), was investigated as a potential TAT agent ([225Ac]Ac-E4G10) for targeting the vascular endothelium of glioblastoma with tumor growth-controlling ability in a mouse model [159].